Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Canadian Fabry Research Consortium University Health Network, Toronto Capital District Health Authority, Canada |
---|---|
Information provided by: | Canadian Fabry Research Consortium |
ClinicalTrials.gov Identifier: | NCT00455104 |
CFDI STUDY with ENZYME REPLACE THERAPY (ERT): Canada-Wide Patient Recruitment
Fabry disease is a rare, inherited, genetic condition due to a deficiency of an enzyme called alpha-galactosidase A. This enzyme deficiency causes the small blood vessels to accumulate a substance called glycolipid. Without sufficient levels of the enzyme, alpha-galactosidase A, persons with Fabry Disease develop severe neuropathic pain, kidney disease, heart disease, stroke and/or premature death; often before the age of 60 years old. Fabry Disease is estimated to affect approximately one out of every 40,000 males and up to twice as many females in Canada. We know there are approximately 225 people living in Canada with Fabry disease, with the largest number living in Nova Scotia. However, we do not have the exact number of persons in Canada who have this disease. A common problem in studying rare conditions is the difficulty in identifying the majority of people suffering from such a disease. Gathering their health information in order to better understand the natural disease progression and its response to treatment is difficult. Until recently, treating symptoms was all that was available for people with Fabry Disease. In 2001, enzyme replacement therapy (ERT) was developed as a treatment for this rare condition. ERT provides the deficient enzyme and may be beneficial in Fabry Disease. The Canadian Fabry Disease Initiative (CFDI) will determine the impact of Enzyme Replacement Therapy (ERT) on the development of complications of Fabry Disease in males and females currently on, or who have received ERT; and to assess which of these complications respond to the ERT therapy. Another purpose of this study is to establish a national registry which will collect information on all persons with Fabry Disease in Canada. Early ERT studies involving humans had small numbers of subjects and the studies were of short duration. The results of these clinical studies did lead to approval of the therapy in many countries around the world including Canada. To date though, evidence of the usefulness of ERT and its direct impact on the natural course of Fabry disease has been limited, while its cost continues to be very high. As a result of these issues, there will need to be continued and long-term collection of information related to the effectiveness of ERT to better document its true clinical outcomes in Canadian people with Fabry disease.
The 5 goals of this nation-wide study are as follows:
Condition | Intervention | Phase |
---|---|---|
Fabry Disease |
Drug: agalsidase alfa (Replagal®) and agalsidase beta (Fabrazyme®) Drug: Enzyme Replacement Therapy (ERT) |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Historical Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Enzyme Replacement Therapy for Fabry Disease: A Model for the Integration of Rare Disease Therapeutics Into the Canadian Health Care System |
Estimated Enrollment: | 250 |
Study Start Date: | January 2007 |
Estimated Study Completion Date: | March 2017 |
Estimated Primary Completion Date: | March 2017 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Cohort 1A: Active Comparator
Cohort 1A are Fabry Disease subjects who are currently on enzyme replacement therapy (ERT) or have had ERT interrupted and will continue the same ERT drug as before. Estimated total of 50 Cohort 1A subjects.
|
Drug: agalsidase alfa (Replagal®) and agalsidase beta (Fabrazyme®)
agalsidase beta (Fabrazyme®)1 mg/kg IV Q2weeks agalsidase alfa (Replagal®)
agalsidase alpha (Replagal) or agalsidase beta (Fabrazyme)
|
Cohort 1B: Active Comparator
Cohort 1B subjects have Fabry Disease and have never received ERT, but now meet the Canadian Fabry Guidelines to initiate ERT. An estimated 100 Cohort 1B subjects will be enrolled in Canada.
|
Drug: agalsidase alfa (Replagal®) and agalsidase beta (Fabrazyme®)
agalsidase beta (Fabrazyme®)1 mg/kg IV Q2weeks agalsidase alfa (Replagal®)
|
Natural Cohort: No Intervention |
CFDI STUDY with ENZYME REPLACE THERAPY (ERT): Canada-Wide Patient Recruitment
There are approximately 250 people in Canada known to have Fabry Disease For more details about Fabry Disease, please refer to the "Brief Summary." The Canadian Fabry Disease Initiative will collect information from 3 different study groups of Fabry subjects recruited from across Canada over a 10-year period.
The 5 goals of this nation-wide study are as follows:
This 3-armed study will consist of 3 study populations. The first group will be referred to as Cohort 1A.
This group includes males and females with Fabry Disease, who are currently on ERT or have had ERT treatment interrupted. We are expecting approximately 50 persons in Cohort 1A in total. The second group, Cohort 1B, will consist of people who have never had ERT, but who now meet the current Canadian guidelines for starting ERT therapy. Approximately 100 subjects will be recruited in Canada.
The third group will be called the Natural History Cohort with approximately 100 Canadian subjects with mild Fabry Disease who currently do not need ERT. For BC, we anticipate recruiting 15 subjects for the Natural History Cohort group. All these numbers are estimates because the exact number of people in Canada with Fabry Disease is unknown at this time.
Data will be collected at baseline and every 6 months for 3 years, as follows:
To date though, evidence of the usefulness of ERT and its direct impact on the natural course of Fabry disease has been limited, while its cost continues to be very high (approximately $300,000 CDN per year per patient). As a result of these issues, there will need to be continued and long-term collection of information related to the effectiveness of ERT to better document its true clinical outcomes in Canadian people with Fabry disease.
Ages Eligible for Study: | 5 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA:
(A) ALL of the following criteria must be met for each CFDI subject in Cohort 1A, Cohort 1B & the Natural
History Cohort:
(B) ALL of the following criteria must be met for each REP001A subject originally enroled as a CFDI Cohort 1A or Cohort 1B subject:
EXCLUSION CRITERIA:
Contact: Michael L. West, MD | 902-473-4032 | mlwest@dal.ca |
Contact: Kaye Le Moine, RN | 902-473-5770 | klemoine@dal.ca |
Canada, Alberta | |
Alberta Children's Hospital | Recruiting |
Calgary, Alberta, Canada, T2T 5C7 | |
Contact: Robin Casey, MD 403-943-7587 robin.casey@crha-health.ab.ca | |
Contact: Colleen McNeil 403-955-7941 colleen.mcneil@calgaryhealthregion.ca | |
Principal Investigator: Robin Casey, MD | |
Canada, British Columbia | |
Vancouver General Hospital Adult Metabolic Diseases Clinic | Recruiting |
Vancouver, British Columbia, Canada, V5Z 1M9 | |
Contact: Sandra Sirrs, MD 604-875-5965 sandra.sirrs@vch.ca | |
Contact: Wendy A Leong, PharmD 604-680-4355 wendy@leong.com | |
Principal Investigator: Sandra Sirrs, MD, FRCPC | |
Canada, Nova Scotia | |
Queen Elizabeth II Health Sciences Centre | Recruiting |
Halifax, Nova Scotia, Canada, B3H 1V8 | |
Contact: Michael L West, MD 902-473-4032 mlwest@dal.ca | |
Contact: Susan Hyndman, RN 902-473-7083 susan.hyndman@cdha.nshealth.ca | |
Principal Investigator: Michael L West, MD | |
Canada, Ontario | |
Hospital for Sick Children | Recruiting |
Toronto, Ontario, Canada, M5G 1X8 | |
Contact: Joe T. Clarke, MD, FRCP(C) 416-813-5340 jtrc@sickkids.on.ca | |
Contact: Tracy Heeney, BSc, CCRP 416-586-4800 ext 4220 tracy.heeney@uhn.on.ca | |
Principal Investigator: Joe Clarke, MD | |
Canada, Quebec | |
University of Montreal, Department of Medicine | Recruiting |
Montreal, Quebec, Canada | |
Contact: Daniel Bichet, MD 514-338-2222 ext 2173 daniel.bichet@umontreal.ca | |
Contact: Carole Fortier, RN 514-338-2216 c-fortier@crhsc.rtss.qc.ca | |
Principal Investigator: Daniel Bichet, MD |
Principal Investigator: | Michael L West, MD | Queen Elizabeth II Health Sciences Centre (Capital District Health Authority), Halifax, Nova Scotia, Canada |
Responsible Party: | Canadian Fabry Research Consortium ( Dr. Michael West ) |
Study ID Numbers: | CFDI 001, REP001A (Replagal) Sub Study |
Study First Received: | March 30, 2007 |
Last Updated: | January 28, 2009 |
ClinicalTrials.gov Identifier: | NCT00455104 History of Changes |
Health Authority: | Health Canada: Ministry of Health & Long Term Care, Ontario |
Fabry Disease Enzyme Replacement Therapy (ERT) |
Lipid Metabolism, Inborn Errors Sphingolipidoses Metabolic Diseases Lysosomal Storage Diseases Rare Diseases Sphingolipidosis Central Nervous System Diseases Brain Diseases Metabolism, Inborn Errors |
Genetic Diseases, Inborn Fabry Disease Genetic Diseases, X-Linked Ceramide Trihexosidosis Brain Diseases, Metabolic, Inborn Lipidoses Metabolic Disorder Lipid Metabolism Disorders Brain Diseases, Metabolic |
Lipid Metabolism, Inborn Errors Sphingolipidoses Metabolic Diseases Lysosomal Storage Diseases, Nervous System Lysosomal Storage Diseases Nervous System Diseases Central Nervous System Diseases Brain Diseases |
Metabolism, Inborn Errors Genetic Diseases, Inborn Fabry Disease Genetic Diseases, X-Linked Brain Diseases, Metabolic, Inborn Lipidoses Lipid Metabolism Disorders Brain Diseases, Metabolic |